Your provider will review medical history, current medications, allergies, endocrine concerns, metabolic risks, pregnancy or breastfeeding status, and contraindications before making any recommendation
They found that for FDA approved GLP-1s for weight loss, liraglutide (Saxenda) and semaglutide (Wegovy), the percent of side effects reported was as follows: Nausea: 42.2% Diarrhea: 21.9% Vomiting: also 21.9% Constipation: 8.4% They report that although the incidence of side effects were similar among medications, semaglutide had the greatest risk of nausea, diarrhea, and vomiting, whereas liraglutide had the greatest risk of upper abdominal pain
Unterach, Austria) and the TIR injection (5 mg/0.5 mL) was obtained from Eli Lilly Italy (Sesto Fiorentino 50019, Italy)
Huang H, Dawicki W, Zhang X, Town J, Gordon JR